How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,720 results for

macrolides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. (Abstract)

Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. Non-cystic fibrosis bronchiectasis ("bronchiectasis") is a chronic airway disease for which little data exist to inform treatment decisions. We sought to compare the risks of respiratory infections in chronic users of inhaled corticosteroids (ICS) versus macrolide monotherapy.We identified a cohort of U.S. Medicare enrollees with a bronchiectasis diagnosis (494.0/494.1) between 2006 and 2014, excluding (...) cystic fibrosis. We defined chronic new use as the first 28+ day prescription of ICS or macrolide monotherapy. We compared characteristics of the exposure cohorts using standardised mean differences (SMD) and computed a propensity score (PS) to account for treatment differences. The risks of acute exacerbation, hospitalised respiratory infection, all-cause hospitalisation, and mortality were compared using PS decile-adjusted Cox regression models.We identified 83 589 new users of ICS and 6500

2019 European Respiratory Journal

42. Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease. (Abstract)

Treatment with a macrolide-containing regimen for Mycobacterium kansasii pulmonary disease. Mycobacterium kansasii is a major pathogen associated with nontuberculous mycobacterial pulmonary disease. For treatment of M. kansasii pulmonary disease, daily therapy with isoniazid, rifampin, and ethambutol is traditionally recommended. Although a regimen containing a macrolide, instead of isoniazid, has been recently recommended, supporting data are limited. We compared the treatment outcomes (...) of a macrolide-containing regimen (macrolide group) and an isoniazid-containing regimen (isoniazid group) on patients with M. kansasii pulmonary disease.A total of 49 patients were identified between January 2002 and December 2016. Treatment outcomes for the isoniazid group (n = 24) and the macrolide group (n = 25) were compared.Baseline characteristics of the isoniazid and macrolide groups were similar. Favorable outcomes did not differ between the isoniazid group (79%, n = 19) and macrolide group (88%, n 

2019 Respiratory medicine

43. An adult case of severe life-threatening Mycoplasma pneumoniae pneumonia due to a macrolide-resistant strain, Japan: a case report. Full Text available with Trip Pro

An adult case of severe life-threatening Mycoplasma pneumoniae pneumonia due to a macrolide-resistant strain, Japan: a case report. Until now, the prevalence of macrolide-resistant Mycoplasma pneumoniae (MP) infection among adult patients has been low, and severe MP pneumonia due to a macrolide-resistant strain has seldom been reported. Here, we describe a rare case of severe life-threatening MP pneumonia due to a macrolide-resistant strain in an adult, which was finally treated (...) with fluoroquinolone and tetracycline after failed treatment with macrolide and corticosteroid.A 39-year-old apparently healthy woman complained of fever and productive cough. Three days after onset, she was admitted to a local general hospital. On admission, her vital signs were stable except for high-grade fever. The patient's chest X-ray and chest computed tomography images revealed subsegmental consolidation in her right lower lobe. Treatment with ampicillin/sulbactam, and azithromycin were initiated under

2019 BMC Infectious Diseases

44. Factors of success of low-dose macrolides in chronic sinusitis: Systematic review and meta-analysis. Full Text available with Trip Pro

Factors of success of low-dose macrolides in chronic sinusitis: Systematic review and meta-analysis. To assess the prognostic factors that predict favorable outcomes of low-dose macrolides (LDMs) in treating chronic rhinosinusitis (CRS).Randomized controlled trials studying the effects of LDMs in treating CRS were included. Data were pooled for meta-analysis. Primary outcome was Sino-Nasal Outcome Test (SNOT). Six prognostic factors: CRS subtypes, serum immunoglobulin (Ig)E level, membered (...) lactone ring of macrolides, concurrent endoscopic sinus surgery (ESS), and dosage and duration of the LDMs were assessed by subgroup analyses.Ten studies (608 patients) met the inclusion criteria. LDMs and placebo were not different in SNOT improvement (standardized mean difference [SMD] = -0.23, 95% confidence interval [CI]: -0.69 to 0.24). Subgroup analyses showed that the effects favored LDMs in the patients with CRS without polyps (SMD = -0.64, 95% CI: -1.01 to -0.27) compared to CRS with polyps

2019 Laryngoscope

45. Macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in Johannesburg, South Africa, 2007-2014. Full Text available with Trip Pro

Macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in Johannesburg, South Africa, 2007-2014. Antimicrobial resistance in Mycoplasma genitalium is rising globally with resultant clinical treatment failure. We investigated the prevalence of mutations in the macrolide and fluoroquinolone resistance-determining regions of M. genitalium in Johannesburg, South Africa, and ascertained their association with HIV serostatus.Stored M. genitalium positive specimens (...) , collected from STI and HIV patients enrolled in the Gauteng STI National Microbiological Surveillance programme (2007-2014) and a large HIV outpatient clinic-based study (2007) in Johannesburg, were tested for antimicrobial resistance.We determined the prevalence of 23S rRNA gene mutations conferring macrolide resistance and mutations in the quinolone resistance-determining regions (QRDR) of the gyrA and parC genes in 266 M. genitalium positive DNA extracts. No macrolide resistance-associated mutations

2019 BMC Infectious Diseases

46. Rapid molecular detection of macrolide resistance. Full Text available with Trip Pro

Rapid molecular detection of macrolide resistance. Emerging antimicrobial resistance is a significant threat to human health. However, methods for rapidly diagnosing antimicrobial resistance generally require multi-day culture-based assays. Macrolide efflux gene A, mef(A), provides resistance against erythromycin and azithromycin and is known to be laterally transferred among a wide range of bacterial species.We use Recombinase Polymerase Assay (RPA) to detect the antimicrobial resistance gene

2019 BMC Infectious Diseases

47. Macrolide therapy for chronic rhinosinusitis: a meta-analysis

Macrolide therapy for chronic rhinosinusitis: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

48. Macrolide Antibiotics and Survival in Patients with Acute Lung Injury

Macrolide Antibiotics and Survival in Patients with Acute Lung Injury PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2012 PedsCCM Evidence-Based Journal Club

49. Bordetella pertussis Infection in Infants and Young Children in Shanghai, China, 2016-2017: Clinical Features, Genotype Variations of Antigenic Genes and Macrolides Resistance. (Abstract)

Bordetella pertussis Infection in Infants and Young Children in Shanghai, China, 2016-2017: Clinical Features, Genotype Variations of Antigenic Genes and Macrolides Resistance.

2018 Pediatric Infectious Dsease Journal

50. Treatment of Macrolide-resistant Mycoplasma Pneumoniae

Treatment of Macrolide-resistant Mycoplasma Pneumoniae Treatment of Macrolide-resistant Mycoplasma Pneumoniae - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Treatment of Macrolide-resistant Mycoplasma (...) . Proportionally, M. pneumoniae has become the most important pathogen for childhood pneumonia after the widespread use of Streptococcus pneumoniae vaccines. M. pneumoniae is routinely treated with antibiotics, and the macrolides antibiotics are the drug of choice for M. pneumonia infection. However, macrolide-resistance rates have increased to 20 and 100% in Asia. In previous studies, the most common mutation point, A2063G, was detected from 23% of local strains in Taiwan. The evolution and spreading

2018 Clinical Trials

51. Effect of Combined β-Lactam / Macrolide Therapy on Mortality According to the Microbial Aetiology and Inflammatory Status of Patients with Community - Acquired Pneumonia. Full Text available with Trip Pro

Effect of Combined β-Lactam / Macrolide Therapy on Mortality According to the Microbial Aetiology and Inflammatory Status of Patients with Community - Acquired Pneumonia. Antibiotic combinations that include macrolides have shown lower mortality rates than β-lactams in monotherapy or combined with fluoroquinolones in patients with community-acquired pneumonia (CAP). However, this effect has not been studied according to the levels of C-reactive protein in CAP with identified microbial cause (...) . In patients with CAP and known microbial cause we aimed to evaluate 30-day mortality of a β-lactam plus macrolide (BL + M) compared with a fluoroquinolone alone or with a β-lactam (FQ ± BL).We analyzed a prospective observational cohort of patients with CAP admitted to the Hospital Clinic of Barcelona between 1996 and 2016. We included only patients with known microbial cause.Of 1,715 patients (29%) with known etiology, a total of 932 patients (54%) received BL + M. Despite lower crude mortality in the BL

2018 Chest

52. Azithromycin susceptibility in Neisseria gonorrhoeae and seasonal macrolide use. Full Text available with Trip Pro

Azithromycin susceptibility in Neisseria gonorrhoeae and seasonal macrolide use. Rising azithromycin nonsusceptibility among Neisseria gonorrhoeae isolates threatens current treatment recommendations, but the cause of this rise is not well understood. We performed an ecological study of seasonal patterns in macrolide use and azithromycin resistance in N. gonorrhoeae, finding that population-wide macrolide use is associated with increased azithromycin nonsusceptibility. These results, indicative

2018 Journal of Infectious Diseases

53. Molecular Basis of Macrolide Resistance in Campylobacter Strains Isolated from Poultry in South Korea Full Text available with Trip Pro

Molecular Basis of Macrolide Resistance in Campylobacter Strains Isolated from Poultry in South Korea We investigated the molecular mechanisms underlying macrolide resistance in 38 strains of Campylobacter isolated from poultry. Twenty-seven strains were resistant to azithromycin and erythromycin, five showed intermediate azithromycin resistance and erythromycin susceptibility, and six showed azithromycin resistance and erythromycin susceptibility. Four Campylobacter jejuni and six (...) susceptibility to erythromycin with twofold to 256-fold MIC change in the presence of phenylalanine arginine ß-naphthylamide (PAßN); the effects of PAßN on azithromycin MICs were limited in comparison to those on erythromycin MICs, and 13 strains showed no azithromycin MIC change in the presence of PAßN. Differences between azithromycin and erythromycin resistance and macrolide resistance phenotypes and genotypes were observed even in highly resistant strains. Further studies are required to better

2018 BioMed research international

54. Estimated Cardiac Risk Associated With Macrolides and Fluoroquinolones Decreases Substantially When Adjusting for Patient Characteristics and Comorbidities Full Text available with Trip Pro

Estimated Cardiac Risk Associated With Macrolides and Fluoroquinolones Decreases Substantially When Adjusting for Patient Characteristics and Comorbidities Some studies have found that antimicrobials, especially macrolides, increase the risk of cardiovascular death. We investigated potential cardiac-related events associated with antimicrobial use in a population of patients with acute myocardial infarction.For 185 010 Medicare beneficiaries, we recorded prescriptions for azithromycin (...) myocardial infarction, number of visits, and the influenza rate. In unadjusted analyses, macrolides and fluoroquinolones were associated with a risk of cardiac events. However, the risk associated with macrolide use was substantially attenuated after adjustment for a wide range of variables, and the risk associated with fluoroquinolones was no longer statistically significant. For example, for azithromycin, the odds ratio for any cardiac event or death was 1.35 (95% confidence interval, 1.27-1.44; P

2018 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

55. Draft Genome Sequence of a Shewanella halifaxensis Strain Isolated from the Intestine of Marine Red Seabream (Pagrus major), Which Includes an Integrative Conjugative Element with Macrolide Resistance Genes Full Text available with Trip Pro

Draft Genome Sequence of a Shewanella halifaxensis Strain Isolated from the Intestine of Marine Red Seabream (Pagrus major), Which Includes an Integrative Conjugative Element with Macrolide Resistance Genes Shewanella halifaxensis strain 6JANF4-E-4 was isolated from the intestine of a red seabream (Pagrus major). Here, we report the draft genome sequence of this bacterium, which includes an integrative conjugative element of the SXT/R391 family, where the macrolide resistance determinants mef(C

2018 Genome Announcements

56. Type M Resistance to Macrolides Is Due to a Two-Gene Efflux Transport System of the ATP-Binding Cassette (ABC) Superfamily Full Text available with Trip Pro

Type M Resistance to Macrolides Is Due to a Two-Gene Efflux Transport System of the ATP-Binding Cassette (ABC) Superfamily The mef(A) gene was originally identified as the resistance determinant responsible for type M resistance to macrolides, a phenotype frequently found in clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes. MefA was defined as a secondary transporter of the major facilitator superfamily driven by proton-motive force. However, when characterizing the mef (...) (A)-carrying elements Tn1207.1 and Φ1207.3, another macrolide resistance gene, msr(D), was found adjacent to mef(A). To define the respective contribution of mef(A) and msr(D) to macrolide resistance, three isogenic deletion mutants were constructed by transformation of a S. pneumoniae strain carrying Φ1207.3: (i) Δmef(A)-Δmsr(D); (ii) Δmef(A)-msr(D); and (iii) mef(A)-Δmsr(D). Susceptibility testing of mutants clearly showed that msr(D) is required for macrolide resistance, while deletion of mef

2018 Frontiers in microbiology

57. Look and Outlook on Enzyme-Mediated Macrolide Resistance Full Text available with Trip Pro

Look and Outlook on Enzyme-Mediated Macrolide Resistance Since their discovery in the early 1950s, macrolide antibiotics have been used in both agriculture and medicine. Specifically, macrolides such as erythromycin and azithromycin have found use as substitutes for β-lactam antibiotics in patients with penicillin allergies. Given the extensive use of this class of antibiotics it is no surprise that resistance has spread among pathogenic bacteria. In these bacteria different mechanisms (...) of resistance have been observed. Frequently observed are alterations in the target of macrolides, i.e., the ribosome, as well as upregulation of efflux pumps. However, drug modification is also increasingly observed. Two classes of enzymes have been implicated in macrolide detoxification: macrolide phosphotransferases and macrolide esterases. In this review, we present a comprehensive overview on what is known about macrolide resistance with an emphasis on the macrolide phosphotransferase and esterase

2018 Frontiers in microbiology

58. Wanted: The Best Second Option to Treat Macrolide-Unresponsive Mycoplasmal Pneumonia in Children Full Text available with Trip Pro

Wanted: The Best Second Option to Treat Macrolide-Unresponsive Mycoplasmal Pneumonia in Children 30344464 2018 11 19 1598-6357 33 43 2018 Oct 22 Journal of Korean medical science J. Korean Med. Sci. Wanted: The Best Second Option to Treat Macrolide-Unresponsive Mycoplasmal Pneumonia in Children. e281 10.3346/jkms.2018.33.e281 Jo Dae Sun DS https://orcid.org/0000-0002-3141-9539 Department of Pediatrics, Chonbuk National University Medical School, Jeonju, Korea. eng Editorial 2018 10 10 Korea

2018 Journal of Korean medical science

59. Phenotypic and genotypic characterization of macrolide, lincosamide and streptogramin B resistance among clinical isolates of staphylococci in southwest of Iran Full Text available with Trip Pro

Phenotypic and genotypic characterization of macrolide, lincosamide and streptogramin B resistance among clinical isolates of staphylococci in southwest of Iran The present study aimed to determine the phenotypic and genotypic profile of macrolide, lincosamide and streptogramin B (MLSB) resistance in clinical isolates of staphylococci.This cross-sectional study was conducted on 164 non-duplicated staphylococci isolates collected during August 2015 to February 2016 from two tertiary care

2018 BMC research notes

60. Characterization of the biosynthetic gene cluster of the polyene macrolide antibiotic reedsmycins from a marine-derived Streptomyces strain Full Text available with Trip Pro

Characterization of the biosynthetic gene cluster of the polyene macrolide antibiotic reedsmycins from a marine-derived Streptomyces strain Polyene antibiotics are important as antifungal medicines albeit with serious side effects such as nephrotoxicity. Reedsmycin (RDM) A (1), produced by marine-derived Streptomyces youssoufiensis OUC6819, is a non-glycosylated polyene macrolide antibiotic with antifungal activity comparable to that of clinically used nystatin. To elucidate its biosynthetic

2018 Microbial cell factories

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>